Search 

Mainly for investment services and project indUnited Statestrialization

A leading national pharmaceutical company in China

China Meheco Group Co.,Ltd is a state holding company listed at Shanghai Stock Exchange (Stock No. 600056).

China Meheco is a domestic leading distributor of pharmaceutical and health care products in China, and it has strong terminal network coverage. Pharmaceutical business has been maintaining a rapid development over the years, and it is an important development force in China.

focus on biotechnology and chinese new economy

foucusing on precision medicine.,biotechnology and digital medicine.

Stated-owned large pharmaceutical corporation, covering R&D, manufacture, and sales of chemical and biological medicine.

We are the flagship subsidiary of China Resources Group, engaging in the research and development, manufacturing, distribution and retail of a broad range of pharmaceutical and healthcare products.In 2018, our total revenue is HK$ 189.7 billion.
Currently CR Pharma Group is one of the TOP 3 pharmacetucial group in China, and our core competences is capabilities are marketing&sales(3000+ Sales Reps for RX and 3000+ Sales Reps for OTC and healthcare products, local Regulatory Affairs(Dedicated RA team), and great manufacturing facilities(40+ manufacturing sites in China, including API and finished products of all dosage forms, 4 sites are approved by US FDA and EMEA).
As a listed company in HK, CR Pharma has estalished consodiated business reputation in healtcare industry and capital market. And currently, nearly all top 50 MNC pharmacetical companies are our business partner in China, and business scope includes JV, Licensing, Commercial Distribution.

China largest PE fund which total size is over ten billion RMB.

China医药创新促进会（原名“China医药工业科研开发促进会”,简称“China药促会”）,英文名称：China Pharmaceutical Innovation and Research Development Association（PhIRDA）,成立于1988年,是经国家民政部登记注册的非营利性全国性4A级社会组织。
China药促会秉承“创新、产业化、国际化”的宗旨,以临床需求为导向,长期致力于“产学研用资”紧密结合,促进医药行业创新发展,已经成为集医药创新研发型企业、科研机构、临床研究机构、创新服务机构和医药投资机构所组成的医药创新产业化促进平台,目前有会员单位144家。China药促会已成立了药物研发专业委员会、药物临床研究专业委员会、医药政策专业委员会、医药创新投资专业委员会和创新研发服务专业委员会,形成了以创新为核心,以促进创新为目标的涵盖药物研发、生产、使用以及投融资的全链条组织构架,并作为国际药品制造商协会联合会（IFPMA）的成员继续拓展国际交流渠道。